These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25804281)

  • 1. Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.
    Yang K; Wang C; Nie L; Zhao X; Gu J; Guan X; Wang S; Xiao T; Xu X; He T; Xia X; Wang J; Zhao J
    J Am Soc Nephrol; 2015 Oct; 26(10):2434-46. PubMed ID: 25804281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Klotho restrain RIG-1/NF-κB signaling activation and monocyte inflammatory factor release under uremic condition.
    He T; Xiong J; Huang Y; Zheng C; Liu Y; Bi X; Liu C; Han W; Yang K; Xiao T; Xu X; Yu Y; Huang Y; Zhang J; Zhang B; Zhao J
    Life Sci; 2019 Aug; 231():116570. PubMed ID: 31207307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Klotho in CKD Breaks One's Heart.
    Fu H; Liu Y
    J Am Soc Nephrol; 2015 Oct; 26(10):2305-7. PubMed ID: 25804282
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.
    Milovanova LY; Taranova MV; Milovanova SY; Kozlovskaya Lysenko LV; Pasechnik AI; Kozlov VV; Beketov VD; Volkov AV; Ratanov M
    Int Urol Nephrol; 2022 Jul; 54(7):1613-1621. PubMed ID: 34718928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23 induces left ventricular hypertrophy.
    Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
    J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
    Xie J; Yoon J; An SW; Kuro-o M; Huang CL
    J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
    Kim HJ; Kang E; Oh YK; Kim YH; Han SH; Yoo TH; Chae DW; Lee J; Ahn C; Oh KH
    BMC Nephrol; 2018 Mar; 19(1):51. PubMed ID: 29506503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S; Fujita S; Kizawa S; Morita H; Ishizaka N
    PLoS One; 2016; 11(7):e0156860. PubMed ID: 27400031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.
    Hu MC; Shi M; Cho HJ; Adams-Huet B; Paek J; Hill K; Shelton J; Amaral AP; Faul C; Taniguchi M; Wolf M; Brand M; Takahashi M; Kuro-O M; Hill JA; Moe OW
    J Am Soc Nephrol; 2015 Jun; 26(6):1290-302. PubMed ID: 25326585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
    Hu MC; Shi M; Gillings N; Flores B; Takahashi M; Kuro-O M; Moe OW
    Kidney Int; 2017 May; 91(5):1104-1114. PubMed ID: 28131398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy.
    Xie J; Wu YL; Huang CL
    Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of uremic toxin indoxyl sulfate-induced endothelial cell dysfunction by Klotho protein.
    Yang K; Nie L; Huang Y; Zhang J; Xiao T; Guan X; Zhao J
    Toxicol Lett; 2012 Nov; 215(2):77-83. PubMed ID: 23085347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating α-klotho levels in CKD and relationship to progression.
    Kim HR; Nam BY; Kim DW; Kang MW; Han JH; Lee MJ; Shin DH; Doh FM; Koo HM; Ko KI; Kim CH; Oh HJ; Yoo TH; Kang SW; Han DS; Han SH
    Am J Kidney Dis; 2013 Jun; 61(6):899-909. PubMed ID: 23540260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
    Lin CY; Hsu YJ; Hsu SC; Chen Y; Lee HS; Lin SH; Huang SM; Tsai CS; Shih CC
    J Mol Cell Cardiol; 2015 Aug; 85():249-61. PubMed ID: 26093151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.
    Calò LA; Vertolli U; Pagnin E; Ravarotto V; Davis PA; Lupia M; Naso E; Maiolino G; Naso A
    Life Sci; 2016 Mar; 148():80-5. PubMed ID: 26872982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinopathy and left ventricular hypertrophy in patients with chronic kidney disease: Interrelationship and impact on clinical outcomes.
    Kim Y; Cho JS; Cho WK; Yoon HE; Hong YA; Chang YK; Yang CW; Kim SY; Hwang HS
    Int J Cardiol; 2017 Dec; 249():372-376. PubMed ID: 29121742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice.
    Yang K; Du C; Wang X; Li F; Xu Y; Wang S; Chen S; Chen F; Shen M; Chen M; Hu M; He T; Su Y; Wang J; Zhao J
    Blood; 2017 May; 129(19):2667-2679. PubMed ID: 28264799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia and left ventricular hypertrophy with renal function decline and cardiovascular events in chronic kidney disease.
    Chang JM; Chen SC; Huang JC; Su HM; Chen HC
    Am J Med Sci; 2014 Mar; 347(3):183-9. PubMed ID: 23426086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy.
    Canziani ME; Tomiyama C; Higa A; Draibe SA; Carvalho AB
    Blood Purif; 2011; 31(1-3):26-32. PubMed ID: 21135546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.